


**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

Claim 1. (canceled)

Claim 2. (previously presented)      A compound of the formula



wherein  $R_1$  is independently selected from the group consisting of H; alkyl; substituted alkyl; alkoxy; halo; substituted alkoxy; hydroxy; trifluoralkyl; nitro; amino; alkylamino; cycloalkylamino; cyano; carboxy; cycloalkyl; phenyl; and substituted phenyl;

$R_2$  is pyridyl;


$B_1$  is hydrogen;

$B_2$  is hydrogen; or  $B_1$  and/ or  $B_2$  are methylene and joined together to form a five or six membered ring;


$Y$  is methylene or carbonyl;

L is selected from the group consisting of


(N-methylene)piperidin-4-yl;




(N-methylene)piperazin-4-yl;



(N-methylene)-4-acetyl-piperidin-4-yl;




and (N-methylene)piperidin-4,4-diyl;




Z is selected from the group consisting of


aryl;




N-sulfonamido;




N-(aryl)sulfonamido;




arylamido;




arylureido;




arylacetamido:




(aryloxy)carbonylamino;



2,3-dihydro-2-oxo-1*H*-benzimidazol-1-yl;



and 1-aryl-2,3-dihydro-4-oxo-imidazol-5,5-diyl;



R<sub>3</sub> is independently selected from the group consisting of C<sub>1-6</sub> alkyl; substituted C<sub>1-8</sub>alkyl; cycloalkyl; substituted cycloalkyl; naphthyl; substituted naphthyl; heteroaryl; and substituted heteroaryl;

R<sub>4</sub> is independently selected from the group consisting of hydrogen; C<sub>1-8</sub>alkyl; C<sub>1-8</sub>alkoxy; substituted C<sub>1-8</sub>alkoxy; hydroxy; halogen; cyano; nitro; amino; C<sub>1-8</sub>alkylamino; and C<sub>1-8</sub>dialkylamino;

R<sub>5</sub> is independently selected from the group consisting of hydrogen; C<sub>1-8</sub>alkyl; C<sub>1-8</sub>alkylcarbonyl; aroyl; carbamoyl; amidino; C<sub>1-8</sub>alkyl; C<sub>1-8</sub>alkylaminocarbonyl; (arylamino)carbonyl; and arylC<sub>1-8</sub> alkylcarbonyl;

R<sub>6</sub> is independently selected from hydrogen and C<sub>1-8</sub>alkyl;

n is 1-2;

m is 0-3;

p is 1-3; and

q is 1-3;


provided that when L is (N-methylene)piperazin-4-yl, then Z is phenyl or naphthyl;  
when L is (N-methylene)piperidin-4-yl, then Z is N-sulfonamido, N(aryl)sulfonamido, 2,3-dihydro-2-oxo-1H-benzimidazol-1-yl, benzamido, phenylureido, phenylacetamido or

(phenoxy)carbonylamino; when L is (N-methylene)-4-acetyl- piperidin-4-yl, then Z is phenyl or naphthyl and Y is carbonyl; and when L is (N-methylene)piperidin-4,4-diyl, then Z is 1-aryl-2,3-dihydro-4-oxo-imidazol-5,5-diyl and Y is carbonyl;

and enantiomers, diastereomers and pharamaceutically acceptable salts thereof.

Claim 3. (previously presented)  
consisting of:







A compound of claim 2 selected from the group



and

Claim 4. (previously presented)  
consisting of:


A compound of claim 2 selected from the group



and

Claim 5. (previously presented)  
consisting of:

A compound of claim 2 selected from the group



and








Serial No. 10/071,483  
Docket No. ORT 1588 USDIV

Claim 6. (canceled)

Claim 7. ( canceled)

Claim 8. (previously presented)  
consisting of:






A compound of claim 2 selected from the group



and

Claim 9. (previously presented)  
consisting of:

A compound of claim 2 selected from the group



and


Serial No. 10/071,483  
Docket No. ORT 1588 USDIV

Claim 10. (canceled)

Claim 11. (canceled)

Claim 12. (withdrawn)  
of:

A compound of claim 2 selected from the group consisting



and

Claim 13. (canceled)

Claim 14. (canceled)

Claim 15. (canceled)

Claim 16. (canceled)

Claim 17. (previously presented) A method of treating disorders and diseases associated with NPY receptor subtype 5 selected from the group consisting of eating disorders, obesity, diabetes, memory loss, epileptic seizures, migraine, sleep disturbances, pain, sexual.reproductive disorders, depression and anxiety comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound of claim 2.

Claim 18. (previously presented) A pharmaceutical composition for the treatment of diseases or disorders associated with the NPY Y5 receptor subtype selected from the group consisting of eating disorders, obesity, diabetes, memory loss, epileptic seizures, migraine, sleep disturbances, pain, sexual.reproductive disorders, depression and anxiety comprising a therapeutically effective amount of a compound of claim 2 and a pharmaceutically acceptable carrier.

Claim 19. (canceled)